3Vote!
thepharmaletter.com (Free subscription) | yesterday
USA-based Intelliject has entered into an exclusive license with French drug major Sanofi-Aventis’ US and Canadian subsidiaries for a novel epinephrine auto-injector for the emergency treatment of anaphylaxis, in the US and Canada territory. Under the deal, Sanofi-Aventis US will be responsible for manufacturing and commercialization, with Intelliject responsible for the on-going...
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 6 hours ago
... and ValuEngines proprietary forecasted one-month return. Also upgraded to a 53 rating was Sanofi-Aventis (NYSE: SNY). Approximately 80 to 85 companies achieve this highest ValuEngine rating out of VEs total coverage of over 5,000 publicly traded companies. ValuEngine is a subscription-based business intelligence, market and equity analysis firm that provides exclusive, customized research...
4Vote!
Medical News Today (Free subscription) | yesterday
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the European Commission has granted marketing authorization for Multaq(R) (dronedarone 400mg Tablets) in all 27 European member states. This approval follows the European Commission positive opinion issued on September 25, 2009 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine agency (EMEA).
Explore : Drug Manufacturers,
European Commission,
European Union,
Health-Fitness,
Health Industries,
Heart Diseases,
International,
Money,
New York Stock Exchange,
NYSE Euronext,
Sanofi-Aventis,
Stock exchange
3Vote!
Pharmalot (Free subscription) | 30/11/2009
Yet another drugmaker looks to shrink its sales team. The combination of patent cliffs, fewer regulatory approvals and, in some cases, drugs that never make it to market is forcing one company after another to throw sales reps overboard. Sanofi-Aventis, which faces a 2011 patent expiration on its Plavix bloodthinner, is the latest to take [...]
3Vote!
PR News Wire (Free subscription) | 30/11/2009
BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).
3Vote!
thepharmaletter.com (Free subscription) | 30/11/2009
Drug major Sanofi-Aventis was in the news on two fronts: it has received final approval to market its arrhythmia drug Multaq (dronedarone) in the European Union and has signed a memorandum of understanding with Prominvest, a wholly-owned subsidiary of the Russian state corporation Rostekhnologii, confirming its intent to participate in the “Pharmpolis Project” using the French company’s...
3Vote!
PharmaGossip (Free subscription) | 30/11/2009
Finished summarizing the list of Vit. & Minerals, now all I have to do is memorize it all. Easy? NOT! I have to study for MCN & Pharma too.
3Vote!
Market Watch (Free subscription) | 30/11/2009
LONDON (MarketWatch) -- French drugmaker Sanofi-Aventis said Monday that the European Commission has granted marketing authorization for Multaq in all 27 European member states. Multaq is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Market Pulse Stories are Rapid-fire,...
3Vote!
Red Orbit (Free subscription) | 30/11/2009
PARIS, November 30 /PRNewswire-FirstCall/ -- - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone - 400mg Tablets) in all 27 European member states.
3Vote!
PR News Wire (Free subscription) | 30/11/2009
PARIS, November 30 /PRNewswire-FirstCall/ --
3Vote!
Market Watch (Free subscription) | 27/11/2009
LONDON (MarketWatch) -- French drugmaker Sanofi-Aventis said Friday that it has signed a memorandum of understanding with Prominvest, a fully owned subsidiary of the Russian State Corporation Rostekhnologii. Sanofi intends to participate in the "Pharmpolis Project" using its insulin factory in Russia. The "Pharmpolis Project" is part of the Russian Government's effort to...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 25/11/2009
Sanofi Aventis (SNY) could be on the move today and is now at $39.12, up $0.49 (1.27%) on volume of 383,435 shares traded. Over the last 52 weeks the stock has ranged from a low of $24.59 to a high of $40.17. Sanofi Aventis stock has been showing support around $38.13 and resistance in the $39.03 range. Technical i...
+Vote!
SeekingAlpha.com (Free subscription) | 5 hours ago
Ohad Hammer submits: For part I click here At ASH 2009, Immunogen ( IMGN ) and its partners will present clinical data on three compounds: Sanofi-Aventis’ ( SNY ) SAR3419 , Immunogen’s IMGN901 and Biotest’s BT-062 . Complete Story »
3Vote!
kansascity.com (Free subscription) | 14 hours ago
Six men have pleaded guilty to methamphetamine charges connected to the 2007 robbery of a Kansas City pharmaceutical manufacturing plant, federal authorities said Tuesday. The 110-pound drum of pseudoephedrine powder stolen Feb. 4, 2007, from the Sanofi-Aventis U.S. plant was used to manufacture more than $1 million worth of methamphetamine, authorities said.
3Vote!
Kansas City Star (Free subscription) | 14 hours ago
Six men have pleaded guilty to methamphetamine charges connected to the 2007 robbery of a Kansas City pharmaceutical manufacturing plant, federal authorities said Tuesday. The 110-pound drum of pseudoephedrine powder stolen Feb. 4, 2007, from the Sanofi-Aventis U.S. plant was used to manufacture more than $1 million worth of methamphetamine, authorities said.
